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A complex of two S100 EF-hand calcium-binding proteins S100A8/A9 induces apoptosis in various cells, especially tumor cells. Using several
cell lines, we have shown that S100A8/A9-induced cell death is not mediated by the receptor for advanced glycation endproducts (RAGE), a
receptor previously demonstrated to engage S100 proteins. Investigation of cell lines either deficient in, or over-expressing components of the
death signaling machinery provided insight into the S100A8/A9-mediated cell death pathway. Treatment of cells with S100A8/A9 caused a rapid
decrease in the mitochondrial membrane potential (ΔΨm) and activated Bak, but did not cause release of apoptosis-inducing factor (AIF),
endonuclease G (Endo G) or cytochrome c. However, both Smac/DIABLO and Omi/HtrA2 were selectively released into the cytoplasm
concomitantly with a decrease in Drp1 expression, which inhibits mitochondrial fission machinery. S100A8/A9 treatment also resulted in
decreased expression of the anti-apoptotic proteins Bcl2 and Bcl-XL, whereas expression of the pro-apoptotic proteins Bax, Bad and BNIP3 was
not altered. Over-expression of Bcl2 partially reversed the cytotoxicity of S100A8/A9. Together, these data indicate that S100A8/A9-induced cell
death involves Bak, selective release of Smac/DIABLO and Omi/HtrA2 from mitochondria, and modulation of the balance between pro- and anti-
apoptotic proteins.
© 2007 Elsevier B.V. All rights reserved.Keywords: Bcl2 protein family; S100/calgranulin; Cancer regression; Drp1; Receptor for advanced glycated endproducts (RAGE); Mitochondrial fission; XIAPAbbreviations:ΔΨm, mitochondrial membrane potential; AIF, apoptosis-inducing factor; BH3, Bcl2 homology 3; BNIP3, Bcl2/adenovirus E1B 19 kD-interacting
protein 3; DD, death domain; DED, death effector domain; DISC, death inducing signaling complex; Drp, dynamin-related protein; DTPA, diethylene triamine
pentaacetate; Endo G, endonuclease G; FADD, Fas-Associated Death Domain; FADD-DN, dominant-negative FADD mutant; HtrA2, high-temperature requirement
A2; IAPs, inhibitors of apoptosis; IM, inner membrane; JC-1, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide; MTT, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; RAGE, receptor for advanced glycation endproducts; ROS, reactive oxygen species; Smac/DIABLO, second
mitochondrial activator of caspases/direct inhibitor of apoptosis binding protein of low PI; XIAP, X-linked inhibitor of apoptosis
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Polymorphonuclear neutrophils, a vital component of the
innate immune response, perform several host-defense functions
such as phagocytosis of invading microorganisms and cell debris,
release of a number of arachidonic acid-derived eicosanoids,
generation of reactive oxygen species (ROS), and release of
proteolytic enzymes as well as bactericidal and cytotoxic pep-
tides. A complex, of two S100 EF-hand proteins, S100A8/A9, is
one component of this system. S100A8/A9 is released from
activated phagocytes and exerts antimicrobial activity as well as
cytotoxicity against various tumour cells [1–3].
S100A8 and S100A9 (also known as calgranulins A and B,
or MRP8 and MRP14 respectively) are members of the S100
multigene subfamily of cytoplasmic EF-hand Ca2+-binding
proteins [4,5]. They are differentially expressed in a wide
variety of cell types and are abundant in myeloid cells. High
expression of S100A8 and S100A9 has been reported in
disorders such as rheumatoid arthritis, inflammatory bowel
disease and vasculitis [5]. The S100A8/S100A9 complex is
located in the cytosol of resting phagocytes and exhibits two
independent translocation pathways when the cells are
activated. Therefore, it has been assumed that membrane-
associated and soluble S100A8/A9 may have distinct cellular
functions. Recent data suggest that intracellular S100A8/A9
might be involved in (phagocyte) NADPH oxidase activation
[6], whereas the secreted form exerts antimicrobial properties
and induces apoptosis [1–3].
S100 proteins are known to bind to RAGE, and this inter-
action is considered to represent a novel proinflammatory axis
involved in several inflammatory diseases. S100 activation
offers an attractive model to explain how RAGE and its pro-
inflammatory ligands might contribute to the pathophysiology
of such diseases (for review see [7,8]). RAGE is expressed in
many cell types, including endothelial cells, smooth muscle
cells, lymphocytes, monocytes and neurons. RAGE comprises
an extracellular region containing three immunoglobulin-like
domains followed by a transmembrane domain and a short
cytoplasmic region. Although intracellular binding partners
have not yet been identified, the cytoplasmic region appears to
be essential for RAGE signaling (for review see [9]). Binding of
ligands to RAGE contributes not only to perturbation of cell
homeostasis under pathological conditions [7], but also to cell
migration and differentiation [10]. Evidence has accumulated
that S100A8/A9 induces cell death through a dual mechanism:
one associated with zinc extraction from the target cells, the
other through binding to the target cell surface, possibly via
ligand-induced receptor activation [1]. While the zinc-chelating
activities have been characterized [11,12], the S100A8/A9 cell
surface receptor and the signaling pathway have not been
identified.
In the present study we provide new, important insight into
the molecular mechanisms of S100A8/A9-induced cell death.
Our data shows that S100A8/A9-triggered cell death, does not
involve RAGE, or FADD-dependent death receptors, but is
mediated by selected components of the mitochondrial death
pathway. We have demonstrated that S100A8/A9-induced celldeath is modulated by Bcl2-family members, and also relies on
mitochondrial release of OMI/HtrA2 and Smac/DIABLO,
but not cytochrome c, AIF, or Endo G. These events are con-
comitant with XIAP cleavage and downregulation of Drp1, that
regulates mitochondrial fission.
2. Materials and methods
2.1. Materials
Cell culture media were purchased from Sigma Co. (Canada, Oakville, ON)
and Gibco (Canada). Cell culture plasticware was obtained from Nunc Co.
(Canada). Diethylene triamine pentaacetate (DTPA) and 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), monoclonal antibody
to human MRP8/14 (FITC-labeled, clone 27 E10, Acris, Germany), rabbit anti-
human Bak, mouse anti-human Bax, mouse anti-human Bcl-XL, rabbit anti-
human Mcl-1, and mouse anti-human BNIP3 were obtained from Sigma
(Sigma-Aldrich, Oakville, CA), rabbit anti-human/mouse Bcl2, rabbit anti-
human/mouse/rat Drp1, anti-human/mouse/rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), rabbit anti-human/mouse/rat Smac/DIABLO, rabbit
anti-human/mouse/rat Omi/HtrA2, mouse anti-human/mouse/rat cytochrome c,
and goat anti-human/mouse/rat endonuclease G (Endo G) were obtained from
Santa Cruz Biotechnologies (USA). 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzimidazolylcarbocyanine iodide (JC-1) was obtained from Invitrogen
Molecular Probes (Canada). Human RAGE-siRNA and siRNA negative control
were obtained from Santa Cruz Biotechnologies (USA). Goat anti-human
RAGE blocking antibody was obtained form R&D Systems (Hornby, ON, CA).
Anti-CD95 IgM was obtained from Upstate Cell Signaling (CA).
2.2. Purification of S100A8 and S100A9 from human neutrophils
Human neutrophils were prepared from leukocyte-rich blood fractions
(“buffy coat”). S100A8/A9 was purified as described earlier [13]. Prior to use,
the proteins were re-chromatographed by anion exchange using a UnoQ column
(BioRad, Munich, Germany). Recombinant protein was produced by bacterial
over-expression as previously described [14]. All experiments were performed
using S100A8/A9 purified from human neutrophils and the results were
confirmed using recombinant S100A8/A9 [14].
2.3. Cell culture
MCF7 (human, estrogen receptor positive breast cancer), MCF7-Bcl2 over-
expressing, MDA-MB231 (human, estrogen receptor negative breast cancer),
Jurkat (human T-cell leukemia), Jurkat-Bcl2 over-expressing, Jurkat FADD-DN,
BJAB (murine B cell leukemia), BJAB FADD-DN, L929 (murine fibrosar-
coma), HEK-293 (human embryonic kidney), and SHEP and KELLY (human
neuroblastomas) were cultured in RPMI-1640 or DMEM (MDA-MB231, L929,
HEK-293) supplemented with 10% fetal calf serum, 100 U/ml penicillin and
100 μg/ml streptomycin. Cells were incubated at 37 °C in a humidified
atmosphere of 5% CO2. Cell cultures were maintained under logarithmic growth
conditions.
2.4. MTT-assay
The cytotoxicity of S100A8/A9 and DTPA towards the above indicated cell
lines was determined by MTT-assay as previously described [15,16]. Cell
viability was calculated as a percentage using the equation: (mean OD of treated
cells /mean OD of control cells)×100 (for each time point the treated cells were
compared with control cells which were treated only with solvent of S100A8/A9
and DTPA).
2.5. Measurement of apoptosis by flow cytometry
Apoptosis wasmeasured using the Nicoletti method [17]. Briefly, cells grown
in 12-well plates were treatedwith S100A8/A9 (100 μg/ml) for the indicated time
intervals. After scraping, the cells were harvested by centrifugation at 800 g for
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iodide (PI) lysis buffer (1% sodium citrate, 0.1% Triton X-100, 0.5 mg/ml
RNase A, 40 μg/ml propidium iodide). The cell nuclei were then incubated for
30 min at 30 °C and subsequently analyzed by flow cytometry. Nuclei to the left
of the G1 peak containing hypodiploid DNAwere considered to be apoptotic.
2.6. Determination of specific S100A8/A9 binding sites on the cell
surface
Harvested cells were washed three times with PBS containing 3% bovine
serum albumin (BSA) and 0.05% sodium azide (NaN3) (B-PBS). A total of 2×10
6
cells were incubated with 10 μg of human S100A8/A9 for 1 h, washed three times
with B-PBS, and then incubated for 30 min in absence of light with 200 μl FITC-
labeled anti-S100A8/A9 antibody (1:50) (murine IgG1 clone 27E10) containing
20 μg/ml propidium iodide in order to gate out dead cells. Finally, they were
washed three times with B-PBS. In order to control for non-specific binding of the
FITC-labeled anti-S100A8/A9, the cells were incubated with FITC-labeled
antibody in the absence of human S100A8/A9 [18]. The stained cells were
analyzed by flow cytometry (FACS-Calibur, Cell Quest Pro software).
2.7. Immunoblotting
The expression of RAGE, XIAP, Bcl2, Bcl-XL, Mcl-1, Bax, Bak and BNIP3
in SHEP cells, that had been treated with 100 μg/ml S100A8/A9 for different
time intervals was determined by Western blotting. In order to prepare cell
lysates, treated cells were harvested, washed once with cold PBS and resus-
pended for 20 min on ice in a lysis buffer: 20 mM Tris–HCl (pH 7.5), 0.5%
Nonidet P-40, 0.5 mM PMSF and 0.5% protease inhibitor cocktail (Sigma). The
lysate was centrifuged at 10,000 g and the supernatant was collected. 30 μg of
total protein was separated by SDS-PAGE and then transferred onto nylon
membranes (Bak dimerization was detected in non-reducing conditions). The
membranes were blocked in 5% non-fat dried milk in Tris-buffered saline–
Tween 0.1% (TBS) (0.05 M Trizma base, 0.9% sodium chloride and 0.1%
Tween-20), then incubated overnight with the primary antibodies at 4 °C. The
membranes were then incubated at room temperature for 1 h with the relevant
secondary antibodies conjugated with HRP, and membranes were developed by
enhanced chemiluminescence (ECL) detection (Amersham-Pharmacia Biotech).
2.8. RNA interference (RNAi)
The target siRNA for RAGE (sc-36374) and a negative control siRNA (sc-
37007) with an irrelevant sequence were purchased from Santa Cruz Biotechnol-
ogies. The cells were grown to 60–80% confluence and then transfected with the
siRNA duplex (final concentration 100 nM) using Lipofectamine (Invitrogen)
according to the manufacturer's instructions. RAGE expressionwas determined by
immunoblotting at 0, 24, 48 and 72 h post-transfection. The transfected cells (72 h
post-transfection) were then treated with 0–80 μg/ml S100A8/A9 for 48 h and the
viability was assessed by MTT-assay.
2.9. Blocking of RAGE with specific blocking antibody
Cells were grown in 96-well plates. After 24 h, they were treated with RAGE
blocking antibody (166 μg/ml) for 1 h, then treated with S100A8/A9 (0–80 μg/ml)
for another 48 h. Viability was assessed using MTT-assay.
2.10. Mitochondrial membrane potential
The assay was performed using a mitochondria-specific cationic dye (JC-1),
which undergoes membrane potential-dependent accumulation in the mitochon-
dria. JC-1 exists as a monomer when the membrane potential (ΔΨm) is lower
than 140 mV and emits green light (540 nm) after excitation by blue light
(490 nM) [19]. At higher membrane potentials, JC-1 monomers are converted to
aggregates that emit red light (590 nm) after excitation by green light (540 nm).
MCF7 and MCF7 Bcl2 over-expressing cells were seeded in black clear-bottom
96-well plates. Following treatment with 100 μg/ml S100A8/A9 for different
time intervals as indicated, the cells were loaded with JC-1 by replacing the
culture medium with HEPES buffer (40 mM, pH 7.4) containing 4.5 g/l glucose(high glucose medium) or 1.5 g/l glucose (low glucose medium), 0.65% NaCl
and 2.5 μM JC-1 for 30 min at 37 °C, then washed once with HEPES buffer.
Fluorescence was measured after a further 90 min (this time period is sufficient
for JC-1 to equilibrate between the cytosol and mitochondrial compartments as
ascertained in preliminary experiments) using a fluorescence plate reader that
allows for the sequential measurement of each well at 2 excitation/emission
wavelength pairs, 490/540 and 540/590 nm. Changes in the ratio between the
measured red (590 nm) and green (540 nm) fluorescence intensities indicate
changes in mitochondrial membrane potential. This ratio was calculated for each
well after the fluorescence intensity of wells containing medium and serum
without cells was subtracted. The ratio of red to green fluorescence in the same
culture depends only on the membrane potential and is independent of other
factors such as cell number and mitochondrial size, shape and density.
2.11. Cell fractionation
Cytoplasmic and mitochondrial fractions were separated by differential
centrifugation [17,20]. Briefly, the cells were treated S100A8/A9 (100 μg/ml),
then harvested and washed once with PBS after the indicated time points. Cells
were resuspended for 5 min on ice in a lysis buffer: 10 mM Tris–HCl (pH 7.8),
1% Nonidet P-40, 10 mM mercaptoethanol, 0.5 mM PMSF, 1 mg/ml aprotinin
and 1 mg/ml leupeptin. An equal amount of distilled water was added to the cells
to enhance lysis. The cells were then sheared by passing them through a 22-
gauge needle. The nuclear fraction was recovered by centrifugation at 600 g for
5 min, and the ‘low-speed’ supernatant was centrifuged at 10,000 g for 30 min to
obtain the mitochondrial (pellet) and cytosolic (supernatant) fractions. The
mitochondrial fraction was further lysed in 10 mM Tris (pH 7.4), 150 mMNaCl,
1% Triton X-100, and 5 mM EDTA (pH 8.0).
2.12. Immunocytochemistry, confocal imaging and electronmicroscopy
Cells were grown overnight on coverslips and then treated with 100 μg/ml
S100A8/A9. After 12 h, they were washed with PBS and fixed in 4% para-
formaldehyde, then permeabilized with 0.1% Triton X-100. To locate cyto-
chrome c, Smac/DIABLO, AIF, and Endo G, the cells were incubated with anti-
cytochrome c mouse IgG (1:100 dilution), anti-Smac rabbit IgG (1:100
dilution), anti-DIABLO rabbit IgG (1:150 dilution), anti-Endo G goat IgG (1:75
dilution), anti-AIF mouse IgG (1:500 dilution), respectively. After three washes
with PBS, the cytochrome c, AIF-antibody complexes were stained with the
corresponding Cy5-conjugated secondary antibodies (Sigma, 1:1500 dilution),
and Endo G, Smac and DIABLO were stained with the corresponding FITC-
conjugated secondary antibodies (Sigma, 1:40 dilution) then washed three times
with PBS. To visualize nuclei, cells were stained with 10 μg/ml DAPI. The
mitochondria were stained with the mitochondria-specific dye Mitotracker Red
CMXRos (Molecular Probes; 200 nM in RPMI medium) for 15 min prior to
fixing. The fluorescent images were then observed and analyzed using an
Olympus-FV500 multi-laser confocal microscope.
For transmission electron microscopy, cells were fixed in 2.5% glutaralde-
hyde in PBS (pH 7.4) for 1 h at 4 °C, washed and fixed in 1% osmium tetroxide,
before embedding in Epon. Transmission electron microscopy was performed
with a Philips CM10, at 80 kV, on ultra-thin sections (100 nm on 200 mesh
grids) stained with uranyl acetate and counterstained with lead citrate.
2.13. Statistical analysis
The results were expressed as means±SD and statistical differences were
evaluated by one-way and two-way ANOVA followed by Tukey's post-hoc test,
using the software package SPSS 11. Pb0.05 was considered significant.
3. Results
3.1. S100A8/A9 kills cancer cells of various histological
origins by apoptosis
The apoptosis-inducing activity of S100A8/A9 was inves-
tigated in the cell lines MCF7, MDA-MB231, Jurkat, BJAB,
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mine the cytotoxic activity of S100A8/A9 (Supplementary
Fig. 1A). To control for the zinc ion-depleting effect of S100A8/
A9, we performed experiments with the membrane-imperme-
able Zn+2 chelator DTPA (Supplementary Fig. 1B). Experi-
ments were repeated using the Nicoletti method, a flow
cytometry technique that detects hypodiploid nuclei typical of
apoptosis, to confirm that cell death was occurring via apoptosis
(data not shown). In a parallel experiment, caspase activation
and PARP-1 cleavage were investigated using SHEP cells,
which were treated with S100A8/A9 (100 μg/ml) for 24 h. Our
results showed significant increase in caspase-3, -9, -6, and -7
and PARP-1 cleavage in treated cells (data not shown).
The tested cell lines showed remarkable differences in
sensitivity with respect to time course and effective dose.
S100A8/A9 at 100 μg/ml induced significant cell death
(Pb0.05) in all cell lines tested, but a 50% drop in cell viability
was determined at different time intervals for the individual
lines (Supplementary Fig. 1A). The EC50 of S100A8/A9
after 48 h of treatment were as follows: MDA-MB231 EC50=
45 μg/ml, SHEP EC50=85 μg/ml, KELLY EC50=110 μg/ml,
and BJAB EC50=35 μg/ml. In contrast, DTPA did not induce
significant cell death in MDA-231, L929, and HEK-293 cells
(Supplementary Fig 1B). We have previously shown that DTPA
cytotoxicity was completely inhibited by Zn+2 co-treatment,
while the apoptosis-inducing activity of S100A8/A9 is only
partially reversed by the addition of zinc [1]. These data
confirmed that the apoptosis-inducing activity of S100A8/A9 is
not entirely dependent on zinc depletion.Fig. 1. Induction of apoptosis by S100A8/A9 does not depend on its interaction
with RAGE. (A) Binding of S100A8/A9 to various cell lines as detected by flow
cytometry. Cells (2×106) were incubated with PBS supplemented with 3% BSA
(B-PBS) and 10 μg/ml S100A8/A9 on ice for 1 h, and washed three times with
cold B-PBS. They were then incubated with FITC-labeled anti-S100A8/A9 for
30 min on ice, and were finally washed three times with cold B-PBS. The FITC-
signal was detected in the FL-1 channel by flow cytometry. The blue histogram
shows non-specific binding and the red shows total signal. Non-specific binding
is the binding of FITC-labeled anti-S100A8/A9 in absence of S100A8/A9.
(B) RAGE expression in various cell lines, detected by Western blot (see the
Materials and methods section for more details). (C) Inhibition of RAGE
expression by specific siRNA, in MDA-MB231 cells. The changes in RAGE
expression, were monitored by Western blot. Scrambled siRNA was used as a
negative control. Cellular proteins were extracted at 0, 24, 48, and 72 h post-
transfection. GAPDH was used as a loading control. (D) Specific binding of
S100A8/A9 to MDA-MB231 (blue), negative control siRNA transfected MDA-
MB231 cells (green), and RAGE-targeting siRNA transfected cells (red). Cells
were harvested 72 h post-transfection and S100A8/A9 binding was monitored
by flow cytometry. The data shows that RAGE-siRNA partially decreased
S100A8/A9 binding to MDA-MB231. (E) Cytotoxicity of S100A8/A9 on
MDA-MB231 cells transfected with RAGE-targeting siRNA or negative control
siRNA. For each time point the treated cells were compared with control cells,
which were treated with culture medium and S100A8/A9 solvent (PBS). Cell
viability was assessed by MTT-assay. Results are expressed as percentage
deviation from control and represent means±SD of four independent
experiments. (F–H) Cytotoxicity of S100A8/A9 on MDA-MB231 (F), HEK-
293 (G), and SHEP cells (H) in the presence of RAGE blocking antibody
(166 μg/ml). Cell viability was assessed by MTT-assay. For each time point the
treated cells were compared with control cells treated with S100A8/A9 solvent
(PBS). Results are expressed as percentage deviation from control and represent
means±SD of four independent experiments.3.2. RAGE is not involved in cell death signaling
by S100A8/A9
Experiments were performed to analyze the specific binding
of S100A8/A9 to certain cell lines and the corresponding levels
of RAGE expression. The indicated cell lines were incubated in
the presence and absence of S100A8/A9, and the amount bound
to the cells was measured by flow cytometry using the FITC-
labeled monoclonal antibody 27E10, which specifically recog-
nizes the S100A8/A9 heterodimer. The fluorescence in the
absence of S100A8/A9 (non-specific binding) was subtracted
from the fluorescence determined in its presence. The data were
analyzed using CellQuest Pro software. All the cell lines inves-
tigated expressed S100A8/A9-specific binding sites (Fig. 1A).
Subsequently, RAGE expression in these cells was confirmed
by Western blotting. As shown in Fig. 1B, RAGE-specific
immunoreactivity was detected in all cell lines.
Fig. 1 (continued ).
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responsible for S100A8/A9's cytotoxicity, RAGE expression in
MDA-MB231 (Fig. 1C), SHEP, and HEK-293 cells (data not
shown) was inhibited by the specific siRNA. The expression
decreased with increasing incubation time, and after 72 h,RAGE protein was nearly undetectable. The specific siRNA
almost completely down-regulated RAGE expression, whereas
the negative control siRNA had no effect. S100A8/A9 binding
to MDA-MB231 cells treated for 72 h with either RAGE-
specific siRNA or negative control siRNA was measured by
Fig. 2. Apoptosis induction by S100A8/A9 is not mediated by FADD-dependent
death receptor pathways. (A,B) Cytotoxicity of S100A8/A9 (100 μg/ml) on
(A) Jurkat or (B) BJAB cells over-expressing FADD-DN. (C) Control
experiment: apoptosis-inducing activity of anti-CD95 antibody (500 ng/ml) on
Jurkat, or Jurkat cells over-expressing FADD-DN. Cell viability was assessed by
MTT-assay. For each time point the treated cells were compared with control
cells treated with S100A8/A9 solvent (PBS). For control of anti-CD95 antibody
the cells were treated with volume of PBS, equal to anti-CD95-antibody. Results
are expressed as percentage of corresponding control and represent the means±
SD of four independent experiments.
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the specific siRNA resulted in significantly lower binding of
S100A8/A9 than in either the untreated or the negative con-
trol siRNA-treated cells, indicating that S100A8/A9 binds to
RAGE.
We next investigated the induction of apoptosis by S100A8/
A9 in MDA-MB231 cells that were treated either with the
specific siRNA to suppress RAGE expression or with the
negative control siRNA. As shown in Fig. 1E, S100A8/A9-
induced cell death levels were similar in both cell populations.
Furthermore, we performed viability assays on MDA-MB231,
SHEP and HEK-293 cells in the presence of S100A8/A9 and a
RAGE-specific blocking antibody (Fig. 1F–H). This experi-
ment confirmed that blocking of RAGE did not prevent
S100A8/A9 from inducing apoptosis. These data confirm that
although RAGE is a receptor for S100A8/A9, RAGE-mediated
signaling is not involved in S100A8/A9-mediated cytotoxicity.
Thus, either another receptor is responsible for S100A8/A9-
mediated pro-apoptotic activity, or S100A8/A9 induces apop-
tosis by a so far undiscovered receptor-independent mechanism.
3.3. S100A8/A9-induced cell death is not dependent on a cell
death pathway involving FADD
In order to gain insight into the S100A8/A9 death signaling
pathway, we investigated the apoptosis-inducing activity of
S100A8/A9 in Jurkat and BJAB cells over-expressing FADD-
DN, which prevents the formation of a functional DISC. Acti-
vation of caspase-8 in these experiments is triggered not only by
CD95-L/Fas-L, but also by TRAIL or activating anti-APO-1
antibodies [21]. We treated the two cell lines and their wild type
controls with 100 μg/ml S100A8/A9 for the indicated time
(Fig. 2A,B). The FADD-DN over-expressing cells did not differ
from the corresponding wild type cells in their sensitivity
towards S100A8/A9. In a control experiment, wild type Jurkat
cells and Jurkat over-expressing FADD-DN were treated with
an agonistic anti-CD95 antibody (Fig. 2C). While wild type
Jurkat cells showed increased cell death with increasing anti-
CD95 concentrations, the Jurkat-FADD-DN cells remained
resistant. These results are in accord with our previous study
demonstrating that S100A8/A9 did not induce caspase-8
activation in HT29/219 and SW742 cells [1].
3.4. Over-expression of Bcl2 partially blocks S100A8/A9-
induced apoptosis
Previous studies have shown that S100A8/A9 causes the
production of reactive oxygen species and that S100A8/A9-
induced cell death is inhibited by N-acetyl-cysteine [1,22].
Hence, we investigated the involvement of mitochondria in
S100A8/A9-induced cell death. Over-expression of Bcl2 has
been shown to block apoptosis that involves the mitochondrial
death pathway [23]. We therefore investigated the induction of
apoptosis by S100A8/A9 in two cell lines over-expressing Bcl2
and the corresponding wild type counterparts. Both Bcl2-over-
expressing cell lines, Jurkat-Bcl2 and MCF7-Bcl2, were
significantly more resistant to S100A8/A9 than the wild typecontrols (Fig. 3A,B). Bcl2-over-expression was not sufficient to
block S100A8/A9-triggered cell death completely. Since Bcl2
over-expression conferred resistance to the apoptosis-inducing
activity of S100A8/A9, we investigated the loss of mitochon-
drial membrane potential (ΔΨm) using JC-1 in these Bcl2 over-
expressing cell lines (Fig. 3C). S100A8/A9 caused a rapid
decrease of ΔΨm in wild type MCF7, while MCF7 cells over-
expressing Bcl2 showed a less pronounced decrease mitochon-
drial depolarization (Fig. 3C).
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proteins Bcl2 and Bcl-XL
Bcl2 and Bcl-XL are two anti-apoptotic members of the large
Bcl2 family of proteins. The protective, anti-cell death effect ofBcl2 is counteracted by Bax and other pro-apoptotic Bcl2-
family members, which heterodimerize with anti-apoptotic Bcl2
proteins. The balance between pro- and anti-apoptotic proteins
determines the fate of the cell [24]. In addition, it was recently
reported that expression of anti-apoptotic Bcl2 family members
played an important role in the preservation of Ψm [25].
Because the balance between anti-apoptotic and pro-apoptotic
members of the Bcl2-family of proteins is important, we
investigated if changes in expression of certain members of this
family occurred in SHEP cells treated with S100A8/A9. Similar
results were obtained in experiments using MCF7 cells (data not
shown). As shown in Fig. 3, S100A8/A9 treatment caused a
decrease in Bcl2 and Bcl-XL levels. The expression of Mcl-1,
Bax, BNIP3 and Bak was not altered (Fig. 3D). These data
indicate that S100A8/A9 affects Bcl2 and Bcl-XL expression,
thereby increasing the ratio of pro- to anti-apoptotic proteins
and facilitating cell death.
3.6. S100A8/A9 triggers selective release of Smac/DIABLO
and Omi/HtrA2, and downregulates DRP1 expression
To further examine the effect of S100A8/A9 on mitochon-
dria, we monitored the release of various factors known to play
a role in the mitochondrial death pathway. During the apoptotic
process, the mitochondrial outer and inner membranes are both
permeabilized resulting in the release of soluble proteins from
the organelle. These include the mitochondrial FAD-dependent
oxidoreductase AIF [26], the mitochondrial nuclease Endo G
[27], and caspase activators: cytochrome c, Smac/DIABLO and
Omi/HtrA2 (for review see [28]).
We therefore treated SHEP, MCF7 and L929 cells with
100 μg/ml S100A8/A9 for 12 h and examined the subcellular
locations of cytochrome c, Smac/DIABLO, Omi/HtrA2, Endo
G and AIF by confocal imaging (Fig. 4A–E). Cytochrome c,
Smac/DIABLO, Omi/HtrA2, AIF and Endo G immunofluores-
cence signals were present in the mitochondria of untreated cells
(Fig. 4A–E, control panel). In contrast, no translocation of AIF
(Fig. 4D, S100A8/A9 panel) or Endo G (Fig. 4E, S100A8/A9
panel) to the nucleus, or release of cytochrome c (Fig. 4A,
S100A8/A9 panel) from mitochondria, was observed after
S100A8/A9 treatment. These results indicate that the release of
AIF, Endo G, and cytochrome c is not involved in S100A8/A9-
dependent cell death. Interestingly, Smac/DIABLO and Omi/
HtrA2 were released selectively from the mitochondria to theFig. 3. The effect of Bcl2 on S100A8/A9-mediated cytotoxicity. Jurkat cells
over-expressing Bcl2 (A), MCF7 cells over-expressing Bcl2 (B), and the
corresponding wild type cells were treated with S100A8/A9 (100 μg/ml) for the
indicated time. For each time point the treated cells were compared to control
cells, treated with S100A8/A9 solvent (PBS). Cell viability was assessed by
MTT-assay. Results are expressed as percentage of corresponding control and
represent the means±SD of four repeats. (C) Bcl2 over-expression decreases the
loss of mitochondrial membrane potential (ΔΨm) after treatment with S100A8/
A9 (100 μg/ml). MCF7, and MCF7 over-expressing Bcl2, were treated with
S100A8/A9 andΔΨmwas determined by flow cytometry, using JC-1 fluorescent
dye. (D) S100A8/A9 treatment lowered the expression of anti-apoptotic proteins
Bcl2 and Bcl-XL. Western blot analysis of Bcl2, Bcl-XL, Mcl-1, Bax, Bak,
and BNIP3 expression in SHEP cell lysates treated with 100 μg/ml S100A8/A9
for 0, 8, 16 and 24 h. GAPDH was included as loading control.
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these proteins are involved in S100A8/A9-induced cell death.
Similar observations were made for MCF7 and L929 cells (data
not shown). Translocation of Smac/DIABLO and Omi/HtrA2
was also confirmed by immunoblotting of the cytosolic and
mitochondrial fractions of S100A8/A9-treated cells (Fig. 4H,I).
Translocation of cytochrome c, Endo G, and AIF was also
investigated with immunoblotting of cytosolic, nuclear and
mitochondrial fractions (data not shown).Fig. 4. The involvement of mitochondrial pro-apoptotic proteins in S100A8/A9-trigg
Omi/HtrA2 (C), AIF (D), endonuclease G (E), and Bax (F) in SHEP cells by confoc
Materials and methods section for further details. Western blot analysis of Bak (G
detection was performed as described in the Materials and methods section. GAPD
mitochondrial ultrastructure in control (K) and SHEP cells which were treated with
morphology of mitochondrial fission inhibition (EM magnification: 8.5×103). (M) S
lysates from SHEP cells treated with 100 μg/ml S100A8/A9 for 0, 12, and 24 h, empl
included as loading control.The release of cytochrome c, Smac/DIABLO, Omi/HtrA2,
AIF and Endo G during apoptosis is known to be regulated by a
subclass of Bcl2 proteins [29–31], including Bax and Bak.
These proteins are in an inactive state in healthy cells, with Bax
predominantly found in the cytosol. However, upon the onset of
apoptosis induced by various death stimuli, including DNA
damage and trophic factor deprivation, they are activated by a
process requiring BH3-only Bcl2 family members [30]. SHEP,
MCF7 and L929 cells were therefore treated with 100 μg/mlered cell death. Cellular localization of cytochrome c (A), Smac/DIABLO (B),
al microscopy. Cells were treated with 100 μg/ml S100A8/A9 for 12 h, see the
), Smac (H), Omi (I), and DRP1 (J) in S100A8/A9-treated cells. Western blot
H was used as loading control. Cellular localization of Smac/DIABLO (K,L)
S100A8/A9 (100 μg/ml) for 24 h (L). S100A8/A9 treatment induces typical
100A8/A9 induced XIAP cleavage in SHEP cells. Western blot analysis of cell
oying anti-XIAP. The 25-kD protein represents the degraded form. GAPDH was
Fig. 4 (continued ).
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investigated by confocal imaging and activation of Bak by
immunoblotting. Treatment with S100A8/A9 did not result in
translocation of Bax to the mitochondria (Fig. 4F, S100A8/A9
panel), but Bak homo-dimerization was detected by immuno-
blotting under non-denaturing and non-reducing conditions
(Fig. 4G).
It has recently been reported that inhibiting one of the
mitochondrial fission machinery proteins, Drp1, prevents the
release of cytochrome c but not of Smac/DIABLO in Bax/Bak-
dependent apoptosis [32]. Mitochondrial fission and fusion are
normal and frequent events in healthy cells. The protein ma-
chinery that underlies mitochondrial fission has been well
characterized and extensively reviewed [33]. In mammalian
cells, the process requires at least three proteins, Drp1, hFis1and MTP18 [34]. Drp1 is a large cytosolic GTPase that trans-
locates to the mitochondria, where it couples GTP hydrolysis
with scission of the mitochondrial tubule. Its receptor at the
mitochondria surface is thought to be hFis1, which is anchored
to the mitochondrial-inter-membrane facing the cytoplasm [34–
36]. The treatment of SHEP cells with S100A8/A9 induced a
significant decrease in Drp1 expression (Fig. 4J). This in turn
induced the selective release of Smac/DIABLO and Omi/HtrA2
(Fig. 4B,C) without Bax translocation (Fig. 4F) but with Bak
activation (Fig. 4G). The inhibition of mitochondrial fission
machinery was confirmed using electron microscopy to study
the ultrastructure of mitochondria in S100A8/A9 treated cells
(Fig. 4L). The ultrastructure of mitochondria in S100A8/A9
treated cells showed typical morphology for the cells that
their mitochondrial fission machinery was inhibited [32]. The
Fig. 4 (continued ).
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them actually inhibited at the stage of fission.
3.7. S100A8/A9 induces proteolytic cleavage of XIAP
XIAP is the most potent and best characterized member of
mammalian IAP family [37,38]. Its caspase-inhibitory effect
may be modified by mitochondria-derived negative regulators
of apoptosis (Smac/DIABLO, Omi/HtrA2), which directly
inhibit XIAP and are also able to promote XIAP phosphoryla-
tion and cleavage [38,39]. The treatment of SHEP cells with
S100A8/A9 resulted in XIAP cleavage. As shown in Fig. 4M,
the 25 kD fragment of XIAP could be detected 12 h after
S100A8/A9 treatment, and the signal is pronounced at the 24 h
time point, thus following the time course of the release of
Smac/DIABLO in S100A8/A9 treated cells (Fig. 4B,C,H,I).4. Discussion
S100A8/A9 is a unique molecule, capable of inducing cell
death through multiple mechanisms that may play a critical role
in cancer regression. S100A8/A9 positive cells, macrophages
and polymorphonuclear leukocytes have been shown to
accumulate along the invasive margin of a cancer [40].
Moreover, S100A8/A9 is released upon cellular activation
[41] and induces apoptosis in malignant cells [1,42].
In order to elucidate the molecular mechanisms of S100A8/
A9-induced cell death, we first compared the kinetics of apo-
ptosis induced by S100A8/A9, and by the extracellular Zn-ion
chelator DTPA. These experiments show that the apoptosis-
inducing activity of S100A8/A9 is different from that of the
membrane-impermeable zinc chelator DTPA. S100A8/A9 was
not only more effective than DTPA (Supplementary Fig. 1A,B),
Fig. 4 (continued ).
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pletely reversed by the addition of zinc ions (data not shown).
Hence, S100A8/A9 appears to induce apoptosis by a mechan-
ism that requires binding to target cells, and is distinct from the
cell death caused by zinc depletion.
It has been proposed that RAGE serves as the receptor for the
S100 family of proteins [7]. Thus, we performed detailed
S100A8/A9 binding studies and analyzed RAGE expression by
Western blot. The results showed that S100A8/A9 binds to all
tested cell lines (Fig. 1A), and this interaction correlates with the
presence of RAGE (Fig. 1B). Importantly, the experiments
involving the inhibition of RAGE expression by specific siRNA,
provided strong evidence that RAGE is a receptor for S100A8/
A9 (Fig. 1C,D). However, these experiments also demonstrated
that RAGE ligation is not involved in the induction of apoptosis
by S100A8/A9 (Fig. 1E). This finding was further supported by
experiments using a RAGE blocking antibody (Fig. 1F–H).
Thus, a second, as yet unidentified receptor might mediate the
apoptosis-inducing activity of S100A8/A9. Our results are
consistent with reports of other putative cell surface-binding
sites for S100A8/A9, including heparan sulfate proteoglycan
[43], carboxylated glycans [44], and FAT/CD36 [45]. Interest-
ingly, S100A8/A9 at low micromolar concentrations has
growth-promoting activity and such activity relies on RAGE
ligation andMAP-kinase dependent pathway [46]. This bimodal
characteristic of S100A8/A9 is similar to another member of the
S100 Ca-binding protein family, namely S100B. S100B, at
concentrations ∼100 nM induces apoptosis in myoblasts in a
RAGE-independent manner [47]. S100B-triggered apoptosis
was associated with ROS production and inhibition of the pro-
survival ERK1/2-kinases. Other reports demonstrate that S100B
behaves either as trophic or toxic factor, depending on
concentration (reviewed by Donato [48]).
It is unlikely that S100A8/A9 triggers cell death via TNF-
receptor-family death receptor. Death signaling via the TNF-
death receptor family molecules typically involves the FADD
adaptor protein [49]. FADD binds (directly or through another
adaptor protein, TRADD) to the receptor via its interaction
domain, DD, and to pro-caspase-8 through DED interactions to
form a complex called DISC. Recruitment of caspase-8 through
FADD leads to auto-cleavage and activation of the caspase [50].
We analyzed S100A8/A9 toxicity in Jurkat and BJAB cells, and
their derivatives over-expressing a dominant-negative FADD-
DN (Fig. 2A,B). These FADD-DN-expressing cells are
protected from apoptosis if treated with anti-CD95 (Fig. 2C).
However, the FADD-DN over-expressing cells did not differ
from the corresponding wild type cells in their sensitivity toward
S100A8/A9, both with respect to time course or effective dose.
This finding is in accord with our previous report showing that
S100A8/A9 did not induce caspase-8 activation [1].
It has been previously reported that treatment of HT29/249
and SW742 cells with S100A8/A9 increases the intracellular
level of ROS, and antioxidants reversed the apoptosis-inducing
activity of S100A8/A9 [1,42]. This prompted us to investigate
the mitochondrial pathway in S100A8/A9-induced cell death
using cellular models in which Bcl2 was over-expressed. Bcl2
family members promote or repress mitochondria-driven, andsome other forms of programmed cell death. One function of the
family is to influence the on/off state of the Mitochondrial
Permeability Transition Pore (MPTP) [51]. For example, over-
expression of Bcl2 reduces apoptosis in some models of neu-
ronal ischemia [52]. Correspondingly, both Jurkat and MCF7
cells over-expressing Bcl2 were significantly more resistant to
S100A8/A9-induced cell death (Pb0.05) than their wild type
counterparts (Fig. 3A,B). Further evidence for the involvement
of the mitochondrial pathway in S100A8/A9-induced cell death
was provided by our study of mitochondrial membrane poten-
tial (Ψm). S100A8/A9 caused a rapid drop inΨm in MCF7 cells.
However, MCF7 cells over-expressing Bcl2 were markedly
protected from S100A8/A9-caused decrease in Ψm (Fig. 3C).
Treatment with S100A8/A9 caused the decrease in expres-
sion of Bcl2 and Bcl-XL (Fig. 3D). It is still unclear exactly how
the Bcl2 family proteins regulate apoptosis. Different models of
regulation have been proposed in the literature. According to
one model, the pro-apoptotic Bax and Bak are maintained in an
inactive conformation through direct interactions with one or
two different anti-apoptotic Bcl2 proteins. In response to an
apoptotic stimulus, BH3-only proteins bind to and neutralize the
anti-apoptotic Bcl2 proteins, thereby releasing Bax and Bak
[25]. Over-expression of Bcl2 or Bcl-XL has been reported to
prevent Bax translocation and activation [53,54]. Furthermore,
it has been reported that certain BH3-only proteins display
selective interaction with specific anti-apoptotic Bcl2 family
members. For instance, it has been reported that Bad interacts
with Bcl2 and Bcl-XL, but not with Mcl-1, whereas Noxa binds
to Mcl-1, but not to Bcl2 and Bcl-XL [25]. According to an
alternative model, certain BH3-only proteins can interact with
the pro-apoptotic proteins and trigger apoptosis by binding
directly to Bax and Bak [25]. Finally, recent data suggest that
anti-apoptotic Bcl2 family members sequester BH3-only
proteins, preventing the activation of pro-apoptotic Bax and
Bak. Eventually, the increasing number of activated BH3-only
protein will overpower the anti-apoptotic Bcl2 proteins' inhib-
itory action, thereby triggering the death by direct activation of
Bax/Bak, or possibly, activation of some other unknown fac-
tor in the cytosol or mitochondria required for Bax/Bak ac-
tivation [25]. In addition it has been showed that mitochondrial
depolarization could be prevented by over-expression of
Bcl2 [25]. Our data indicate that high levels of Bcl2 ex-
pression partially protected from S100A8/A9-triggered ΔΨm
(Fig. 3C).
The release of cytochrome c is usually associated with Smac/
DIABLO and Omi/HtrA2 in the apoptotic process after treat-
ment with apoptosis inducers and other forms of cell stress [55–
57]. However, in our study we failed to detect cytochrome c
release, while Smac/DIABLO and Omi/HtrA2 were translo-
cated to cytosol in S100A8/A9-treated cells (Fig. 4A–C,H,I).
These observations are surprising because several papers have
reported that the mitochondrial-inter-membrane proteins, cyto-
chrome c, Smac/DIABLO and Omi/HtrA2 are released together
with the same or similar kinetic pattern [57–59]. These proteins
are mainly soluble in the inter membrane space. However, AIF
is anchored to the inner membrane [60] and endonuclease G is
likely mainly localized in the matrix [61], which would explain
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death as well as in other models.
Recently, a new model has emerged based on the discov-
ery that cytochrome c is differentially released from other
mitochondrial-inter-membrane proteins induced by Bax/Bak-
dependent apoptosis in Drp1-depleted cells [32]. We showed
that S100A8/A9-induced cell death was not Bax dependent, but
Bak was activated and Drp1 expression was decreased. An
explanation for the differential release of cytochrome c and
Smac/DIABLO and Omi/HtrA2 in Drp1-depleted cells may be
that the latter proteins are not as tightly bound to the mito-
chondria as cytochrome c [59]. Indeed, cytochrome c binds to
protein partners (subunits of complexes III and IV) and phos-
pholipids, in particular cardiolipin, through electrostatic inter-
actions [62–64]. This implies that cytochrome c is more tightly
bound to its interaction partners in Drp1-depleted cells than in
control cells. Therefore our findings correlated and confirmed
the recent findings on selective release of Smac/DIABLO and
Omi/HtrA2 in the cells which mitochondrial fission machinery
has been inhibited.
Mammalian Smac/DIABLO and Omi/HtrA2 have the ability
to bind and antagonize the actions of IAPs. Cytosolic Omi/
HtrA2 also contributes to both caspase-dependent and caspase-
independent apoptosis [37]. Omi/HtrA2 interacts with cytosolic
IAP proteins similar to Smac/DIABLO [56]. However, in
contrast to Smac/DIABLO, HtrA2 also promotes the catalytic
cleavage of IAPs leading to their irreversible inactivation and
the progression of apoptosis [39]. Our finding that these pro-
teins are selectively released from mitochondria in S100A8/A9-
treated cells (Fig 4B,C) was confirmed by XIAP degradation to
a 25-kD fragment (Fig. 4M).
In conclusion, the present study demonstrates that S100A8/
A9 exerts cytotoxic activity in a broad range of cell lines. RAGE
ligation is not involved in the death signaling activity of this
protein but a second cell surface-binding site mediates the
induction of apoptosis. S100A8/A9 decreases Ψm and causes
Bak activation as well as decreased expression of Bcl2 and Bcl-
XL. In addition, S100A8/A9-induced cell death decreases Drp1
expression and provokes the selective translocation of Smac/
DIABLO and Omi/HtrA2 from mitochondria to cytoplasm and
subsequent XIAP degradation. In this study, we also report that
inhibiting Drp1-mediated mitochondrial fission does not
prevent Bak-mediated cell death, although it prevents cyto-
chrome c release. Our results are in agreement with other time
course study demonstrating that knock down of Drp1 does not
inhibit apoptosis [32]. Hence, by tracing S100A8/A9 activity in
cell death, this study provides an important insight into the
molecular mechanism of the S100A8/A9 cell death pathway. It
also provides an avenue for a better understanding of how
S100A8/A9 released from activated phagocytes might be in-
volved in the response of the innate immune system against
tumors.
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